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Abstract 
Adoptive T-cell therapy, or the use of autologous T cells to seek and destroy 
diseased cells, is a promising treatment option for opportunistic diseases, virus-associated 
malignancies, and cancers. However, the safety and efficacy of adoptive T-cell therapy 
depend, in part, on the ability to sustain and tightly regulate the proliferation of 
transferred T cells in vivo. The emerging field of synthetic biology provides powerful 
conceptual and technological tools for the construction of regulatory systems that can 
interface with and reprogram complex biological processes such as cell growth. Here, we 
present the development of RNA-based regulatory systems that can control T-cell 
proliferation in a ligand-dependent manner, and examine the construction of integrated 
control systems capable of fine-tuned programming of cellular behavior.  
We systematically investigate the translation of ribozyme-based regulatory 
devices from yeast to mammalian cells and identify design parameters critical to the 
portability of regulatory devices across host organisms. We report the construction of 
ligand-responsive ribozyme switch systems capable of modulating the transgenic 
expression of growth-stimulatory cytokines in mammalian lymphocytes. We demonstrate 
the ability of ribozyme switch systems to regulate T-cell proliferation in primary human 
central memory T cells and in animal models. We further develop ligand-responsive, 
miRNA-based devices to regulate the endogenous expression of cytokine receptor chains 
and the functional output of cytokine signaling pathways, highlighting the ability to 
construct integrated T-cell proliferation control systems employing various regulatory 
mechanisms to modulate multiple components in relevant signaling pathways. Finally, 
we describe efforts in the generation of novel RNA aptamers to clinically suitable 
 vii 
molecules, which can serve as the molecular inputs for ligand-responsive, RNA-based 
control systems in therapeutic applications. 
The regulatory systems developed in this work are designed to be modular and 
transportable across host organisms and application contexts, thus providing a template 
for future designs in RNA-based genetic regulation. This work demonstrates the 
capability of RNA-based regulatory systems to advance next-generation treatment 
options for critical diseases, and highlights the potential of synthetic biological systems to 
achieve novel and practical functions in diverse applications.  
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